Cardinal Health Reports Strong Q2 Results, Raises FY26 EPS Guidance Amidst Broad Segment Growth

summarizeSummary

Cardinal Health reported strong second-quarter fiscal year 2026 results, with significant revenue and earnings growth, and raised its full-year non-GAAP EPS guidance.

check_boxKey Events

• Strong Q2 FY26 Financial Performance

  Revenue increased 19% to $65.6 billion, non-GAAP operating earnings rose 38% to $877 million, and non-GAAP diluted EPS grew 36% to $2.63.

• Raised Fiscal Year 2026 Outlook

  The company increased its non-GAAP diluted EPS guidance for fiscal year 2026 to a range of $10.15 to $10.35, representing 23% to 26% growth.

• Broad Segment Profit Growth

  All operating segments achieved double-digit profit growth, including Pharmaceutical and Specialty Solutions (+29%), Global Medical Products and Distribution (+106%), and Other (+52%).

• Capital Allocation and Financial Health

  Cardinal Health completed an additional $375 million accelerated share repurchase program, bringing year-to-date repurchases to $750 million, and reached its targeted leverage range.

auto_awesomeAnalysis

Cardinal Health delivered a robust second quarter, significantly exceeding prior-year performance across key financial metrics and raising its full-year guidance. The substantial growth in revenue, operating earnings, and diluted EPS, coupled with double-digit profit increases across all operating segments, indicates strong operational execution and market demand. The raised fiscal year 2026 non-GAAP EPS guidance provides a positive outlook, reinforcing investor confidence, especially as the company is trading near its 52-week high. Furthermore, the completion of $750 million in share repurchases and achieving its targeted leverage range demonstrate sound capital management and financial stability.